Fundraising FoxSymBiosis
Venture capitalBentonville · Seed–Late Stage · 4 people tracked
Also known as SYMBIOSIS CAPITAL PARTNERS, LLC
Find your way into SymBiosis
Each arrow is one introduction. Sign up to fill in the first one.
Ask Adam Coffman to introduce you to Allie Ivy
You →Adam · together at University of Arkansas →Allie
Sign up to find every way you can get introduced to SymBiosis
- Your email: who you already know at SymBiosis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the SymBiosis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
SymBiosis invests in biotherapeutic companies across multiple stages, with emphasis on programs in or approaching clinical trials, across various disease indications. The firm operates globally through dedicated funds designed to support long-term investments.
Source: firm website, verified Aug 25, 2026.
Team · 4 people
from public directories
What they invest in
from 11 of 11 portfolio companiesBiotech ×10Healthtech ×8Deep Tech ×4Medical Devices ×4AI & Machine Learning ×3Digital Health ×1EdTech ×1HR Tech ×1
HQs:United States×9Israel×1
Investments · 11 tracked
founders shown can be your intro pathBy year:2026 · 22024 · 12023 · 12021 · 22020 · 17 dated
Clene is a clinical-stage biopharmaceutical company developing nanotherapeutics that target cellular energy impairments to treat neurodegenerative diseases and restore neuronal health.
BiotechDeep TechHealthtechSalt Lake City, US
Mark Mortenson(Executive Officer)inReed N. Wilcox(Independent Director)Morgan Brown(Executive Officer)inRobert Glanzman(Executive Officer)inTae Heum Jeong(Executive Officer)Robert Etherington(President, Chief Executive Officer, and Director)
Board seatChidozie Ugwumba· per SEC Form D · $9.3M raise · filed May 2021
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Board seatChidozie Ugwumba· per SEC Form D · $70.4M raise · filed Jan 2021
Co-investorsAgent CapitalAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures Fund+3 more
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalQuery CapitalTruVenturo GmbH+4 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+13 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+9 more
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM Healthcare InvestmentsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture Capital+4 more
Kernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Yusuf Erkul(Founder)inJeff Ozdemir(Founder)inBurak Yilmaz(Founder)inBurak YILMAZ(Founder)inCatherine Moroski(Executive Officer, Director)inOguzhan Yilmas(Director)
Co-investorsAsymmetry VenturesCivilization Ventures Management, LlcFoundersX VenturesHOF CapitalHummingbird VenturesSAV (Scale Asia Ventures)+13 more
Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSalt Lake City, US
Andrea Mazzocchi(Co-founder, PhD)inKatie-Rose Skelly(Co-founder, MS)in
Co-investorsY CombinatorCota CapitalForward Venture CapitalCaffeinated CapitalFORWARD.oneKhosla Ventures+3 more
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupViking GlobalYsios CapitalAlexandria+8 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more
Tailor-ED develops personalized learning experiences using learning science principles.
AI & Machine LearningEdTechHR TechSaaSTel Aviv-Yafo, IL
Yael Cohen Haramaty(Founder)inMaayan Yavne(Founder)in
Co-investorsY CombinatorARC VENTURESBenson Oak Venturesfresh.fundLucas Venture Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
1 IPOs · 1 acquisitions · showing 1CleneNASDAQ: CLNN
Portfolio news
latest coverage across their companiesFore Biotherapeutics · finsmes.com · Jul 8, 2026
SonoThera · finsmes.com · Jun 10, 2026
Ensoma · finsmes.com · Sep 23, 2025
Frequently asked questions
- How many investments has SymBiosis made?
- SymBiosis has 11 tracked investments, 2 of which have exited, including 2 dated in the last 24 months.
- What stage does SymBiosis invest at?
- SymBiosis invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does SymBiosis focus on?
- SymBiosis focuses on Biotech.
- Where is SymBiosis located?
- SymBiosis is headquartered in Bentonville, US.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.